Background and Purpose-Evidence suggests that some proton pump inhibitors can attenuate the antiplatelet effect of clopidogrel. The significance of this potential drug interaction in patients with cerebrovascular disease is unknown. Methods-We conducted a nested case-control study of all Ontario residents aged Ն66 years newly treated with clopidogrel after a stroke between April 1, 2002, and September 30, 2008. In the primary analysis, case patients were those readmitted for stroke, and a secondary analysis examined all-cause mortality. For each case, up to 4 event-free control subjects were matched on age, gender, and outcome type (stroke or transient ischemic attack). Exposure to proton pump inhibitors was categorized as current (within 60 days), previous (61 to 180 days), or remote (181 to 365 days). Results-Among 2765 patients entering the cohort, we identified 118 cases readmitted for stroke and 472 control subjects.
latelet aggregation plays an important role in the pathogenesis of stroke, and drugs that interfere with platelet function are an important element of treatment. Antiplatelet drugs such as aspirin and clopidogrel are widely prescribed for secondary stroke prevention in patients after ischemic stroke or transient ischemic attack (TIA). A prodrug, clopidogrel is metabolized by the liver to an active metabolite that irreversibly inhibits the platelet P2Y 12 ADP receptor. 1, 2 This bioactivation is mediated by various cytochrome P-450 isoenzymes with cytochrome P-4502C19 (CYP2C19) playing a major role. 3 Loss-offunction polymorphisms in the gene encoding for CYP2C19 are associated with lower levels of the active metabolite of clopidogrel, diminished platelet inhibition during clopidogrel treatment, and an increased risk of cardiovascular events. 4, 5 Recently studies have explored the possibility that some proton pump inhibitors (PPIs) may interfere with the effect of clopidogrel by inhibiting CYP2C19, hindering enzymatic conversion to its active metabolite. Several in vitro studies demonstrate that omeprazole and other PPIs can attenuate the antiplatelet effect of clopidogrel, 6 -8 but the clinical significance of this drug interaction is disputed. Some research suggests that PPIs may be associated with an increased risk of adverse cardiac events, including recurrent myocardial infarction as well as hospitalization for acute coronary syndrome and death in patients taking clopidogrel, 9 -11 whereas other studies find no such association. 12, 13 No published studies have specifically explored the potential drug interaction between PPIs and clopidogrel in patients with cerebrovascular disease. In contrast to coronary artery disease, dual antiplatelet therapy is not generally recommended for long-term secondary stroke prevention. 14, 15 Consequently, PPI-mediated attenuation of clopidogrel's effect may assume particular importance in patients receiving clopidogrel as the sole antiplatelet agent after stroke. In this study, we sought to characterize whether the concomitant use of a PPI with clopidogrel was associated with an increased risk of adverse outcomes among older patients discharged from the hospital after stroke.
Methods

Setting
We conducted a population-based nested case-control study among residents of the province of Ontario, Canada, aged Ն66 years, who were discharged from the hospital after ischemic stroke between April 1, 2002, and September 31, 2008 . These individuals have universal access to hospital care, physicians' services, and prescription drug coverage. The study was approved by the research ethics board of Sunnybrook Health Sciences Centre.
Data Sources
We identified hospital visits using the Canadian Institute for Health Information Discharge Abstract Database, which contains detailed diagnostic and procedural information regarding hospital admissions. All hospitalizations in Ontario are identified in this database, which is population-based and comprehensive. We examined the computerized prescription records of the Ontario Public Drug Program Benefit Program, which contains comprehensive records of prescription medications dispensed to Ontario residents Ն65 years of age. We used the Ontario Health Insurance Plan database to identify claims for inpatient and outpatient physician services. Basic demographic information, including date of death, was identified using the Registered Persons Database, which contains a unique entry for all Ontario residents ever issued a health card. These databases are routinely used to study drug safety, 16 -18 including the clinical consequences of drug-drug interactions, 19 -21 and were linked in an anonymous fashion using encrypted 10-digit health card numbers.
Identification of Patients and Outcomes
We established a cohort of patients aged Ն66 years who filled a prescription for clopidogrel within 30 days of hospital discharge after ischemic stroke or TIA. The date of discharge from the hospital served as the date of cohort entry. We excluded patients who received clopidogrel in the year before hospitalization, or ticlopidine or dipyridamole in the 90 days before hospitalization, as well as patients in long-term care facilities and those who received PPI combination products used to eradicate Helicobacter pylori in the year preceding the index date or 90 days thereafter. Finally, we excluded patients who underwent carotid endarterectomy within 90 days after hospitalization, as well as those readmitted for stroke between the cohort entry date and the first prescription for clopidogrel.
Patients were followed during clopidogrel therapy for a maximum of 180 days from hospital discharge or until readmission for ischemic stroke or TIA. Ongoing use of clopidogrel was assured using an adherence algorithm that required prescription refills of the drug at intervals not exceeding 50% of the days supplied with the preceding prescription. Hospitalizations were identified using the International Classification of Disease and Related Health Problems, 10th Revision for ischemic stroke (I63, I64) and TIA (G45). The date of hospital readmission for stroke or TIA (in the primary analysis) or death (in the secondary analysis) served as the index date. Only the first readmission was considered for patients with multiple readmissions during the study period.
We defined cases as patients who experienced an outcome of interest within 180 days of discharge after stroke. For each case, up to 4 control subjects were sampled randomly with replacement 22 from the same cohort of patients and were required to be event-free but at risk on the index date. Control subjects were matched to cases on age (born within 1 year), gender, and outcome type (stroke or TIA). When Ͻ4 control subjects could be matched to a case patient, we used only those control subjects and did not alter the matching algorithm.
Exposure to PPIs
We used prescription records to determine exposure to PPIs during clopidogrel therapy, including omeprazole, rabeprazole, pantoprazole, and lansoprazole. We did not study esomeprazole because it was not an insured benefit of the provincial formulary during the 
Statistical Analysis
We used conditional logistic regression to estimate the odds ratio (OR) for the association between stroke readmission and PPI exposure using as the reference a group of patients with no prescription for a PPI. We adjusted for the Charlson comorbidity index, 23 the number of drugs dispensed in the previous year, and history of diabetes, stroke, or coronary revascularization in the preceding 5 years. We also adjusted for use of medications that might influence the risk of stroke recurrence, including angiotensinconverting enzyme inhibitors, angiotensin receptor blockers, aspirin, ␤-adrenergic receptor antagonists, calcium channel blockers, statins, other lipid-lowering agents, thiazide diuretics, other diuretics and warfarin. We also adjusted for use of other common cardiovascular medications, other cytochrome P-450 2C19 inhibitors or inducers, and other cytochrome P-450 3A4 inhibitors or inducers 24 (Appendix) between hospital discharge and the reference date. All analyses were performed using SAS Version 9.2 (SAS Institute, Cary, NC).
Results
Over the 78-month accrual period, we identified 2765 patients aged Ն66 years who commenced treatment with clopidogrel within 30 days of hospital discharge after acute ischemic stroke. The median age of these patients was 78 (interquartile range, 73 to 83 years), and 1295 (46.8%) were men. The median length of stay during this admission was 4 days (interquartile range, 3 to 8 days). Postdischarge use of PPIs was common, with 752 (27.2%) patients receiving a PPI within 90 days of discharge.
From this cohort, we identified 118 patients who were readmitted for ischemic stroke or TIA within 180 days of discharge, along with 472 control subjects. The characteristics of cases and control subjects are shown in Table 1 . As expected, cases were more likely than control subjects to have had several comorbidities during their index admission. In the primary analysis, after multivariable adjustment, we found no significant association between readmission for stroke and current use of a PPI in patients receiving clopidogrel (adjusted OR, 1.05; 95% CI, 0.60 to 1.82; Table 2 ). Similarly, in the secondary analysis, we found no statistically significant association between PPI use and death from any cause among older patients taking clopidogrel after stroke (adjusted OR, 1.84; 95% CI, 0.88 to 3.89; Table 3 ).
Discussion
We found that among older patients treated with clopidogrel after acute ischemic stroke or TIA, concomitant use of a PPI was not associated with a significantly increased short-term risk of readmission for stroke. To our knowledge, this is the first study to examine the potential effect of PPI therapy on recurrent stroke risk in patients treated with clopidogrel for secondary stroke prevention.
Although in vitro studies suggest that some PPIs, in particular omeprazole, can attenuate the antiplatelet activity of clopidogrel, 6,25 our findings suggest that this potential drug interaction is of little clinical consequence in patients with cerebrovascular disease. This observation differs from previously published research by our group 9 and others 10,11 in patients with acute coronary syndromes. 23 length of stay in the hospital during the first admission for stroke, hospital type (regional stroke center, district stroke center, or other), and history of diabetes, stroke, or coronary revascularization in the preceding 5 years, use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aspirin, ␤-adrenergic receptor antagonists, calcium channel blockers, statins, other lipid-lowering agents, thiazide diuretics, other diuretics and warfarin, other cytochrome P-450 2C19 inhibitors or inducers, and other cytochrome P-450 3A4 inhibitors or inducers.
†Cells with Ͻ6 observations are suppressed in accordance with institutional privacy policy. 23 length of stay in the hospital during the first admission for stroke, hospital type (regional stroke center, district stroke center, or other), and history of diabetes, stroke, or coronary revascularization in the preceding 5 years, use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aspirin, ␤-adrenergic receptor antagonists, calcium channel blockers, statins, other lipid-lowering agents, thiazide diuretics, other diuretics and warfarin, other cytochrome P-450 2C19 inhibitors or inducers, and other cytochrome P-450 3A4 inhibitors or inducers.
†Cells with Ͻ6 observations are suppressed in accordance with institutional privacy policy.
Some limitations of our research merit emphasis. We had no data on some important risk factors for stroke such as atrial fibrillation, hypertension, and smoking. Although cases and control subjects were matched on important predictors of outcome, some imbalance is evident in their measured characteristics (Table 1) . However, this observation is neither unexpected nor a threat to our primary conclusion, because any bias introduced by this imbalance would tend to favor a spurious association. Miscoding is a potential threat to the validity of all observational studies, but previous validation studies indicate that coding for stroke in Ontario's administrative databases is very good and comparable to that of other administrative databases. 26 -29 We did not have a sufficient sample size to explore the possibility that some PPIs may be associated with greater risk than others. This is particularly important because the largest body of in vitro data on this drug interaction implicate omeprazole, whereas pantoprazole appears to be relatively devoid of an effect on clopidogrel's metabolism and does not interfere with its antiplatelet effect. 8, 25, 30 Importantly, because some patients take PPIs intermittently, misclassification of exposure status is possible in our analysis. However, there is no reason to believe that case and control subjects would differ in this regard.
Stroke is heterogenous and the effectiveness of clopidogrel is expected to be greatest in the subgroup of patients with stroke with large artery atherosclerotic disease rather than those with lacunar disease, cardioembolism, or stroke from other causes. Because administrative databases do not provide reliable information on the etiologic classification of stroke events, we were unable to investigate this interaction in specific subtypes of stroke. Finally, our relatively modest sample size may have limited our ability to detect an association. However, this limitation tends to jeopardize statistical precision, and the point estimate associated with our primary analysis (1.05) suggests that a meaningful Type II error is unlikely.
In summary, we found that among patients treated with clopidogrel after stroke, the concomitant use of PPIs is not associated with an increased risk of readmission for recurrent stroke. This finding should reassure clinicians and patients that treatment with a PPI, when indicated, appears generally safe with respect to stroke recurrence risk in patients receiving clopidogrel. However, this is a rapidly evolving area, and when a PPI is indicated, we believe it is advisable to preferentially use pantoprazole, which exhibits relatively little inhibition of CYP2C19 31 and may not attenuate the antiplatelet effect of clopidogrel to the same extent as other PPIs, particularly omeprazole. 8, 31, 32 
